Vertex Pharmaceuticals Analysts Raise Their Forecasts Following Q3 Results

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) reported mixed results for the third quarter on Monday.

The company posted quarterly earnings of $4.76 per share which missed the analyst consensus estimate of $4.82 per share. The company reported quarterly sales of $3.441 billion which beat the analyst consensus estimate of $3.417 billion.

Vertex Pharmaceuticals raised its FY2026 sales guidance from $13.100 billion-$13.200 billion to $13.150 billion-$13.250 billion.

“Vertex delivered excellent third quarter results marked by strong revenue growth across the increasingly diversified portfolio, continued advancement of the R&D pipeline, and the successful close of the Crinetics Pharmaceuticals acquisition,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “With the potential povetacicept approval in IgAN coming later this month, we are well positioned to establish nephrology as our fifth commercial franchise and expand the reach of our transformative medicines to even more patients.”

Vertex Pharmaceuticals shares gained 2.7% to $567.99 in pre-market trading.

These analysts made changes to their price targets on Vertex Pharmaceuticals following earnings announcement.

• Cantor Fitzgerald analyst Carter Gould maintained the stock with an Overweight rating and raised the price target from $595 to $619.
• Stifel analyst Paul Matteis maintained the stock with a Hold and raised the price target from $500 to $563.

Considering buying VRTX stock? Here’s what analysts think:

Photo via Shhutterstock